AIM ImmunoTech Inc. (NYSE American: AIM) is an immuno-pharma company focused on the research and development of new therapeutics to treat seriously debilitating immune disorders, viral diseases and multiple types of cancers. AIM’s flagship products include Argentina-approved drug rintatolimod (trade names Ampligen(R) or Rintamod(R)) and FDA-approved drug Alferon N Injection(R). Uses will require additional clinical trials to confirm the safety and effectiveness data necessary to support regulatory approval and additional funding. Rintatolimod is a double-stranded RNA candidate being developed for globally important debilitating diseases and disorders of the immune system. For more information, visit the company’s website at www.aimimmuno.com
To view IBN’s virtual coverage of Investor Summit Group’s Q1 Virtual Summit, visit https://ibn.fm/2021InvestorSummitQ1
About InvestorBrandNetwork’s Virtual Coverage
The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the publicly traded companies participating virtually at Investor Summit Group’s Q1 Virtual Summit. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of the event.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]